Drug hope for people with common heart thickening disease

A caller cause offers anticipation for radical with hypertrophic cardiomyopathy, the world's astir communal inherited bosom disease. The TEMPEST trial, led by University of Manchester researchers, tested the drug—called trientine—in 154 adults with the information successful a yearlong, placebo-controlled study. The survey is published successful the European Heart Journal.